SUMMARY AND EXPLANATION OF THE TEST

Preterm delivery, defined by the American College of Obstetricians and Gynecologists as delivery prior to the 37th week of gestation, is responsible for the majority of non-chromosomal perinatal morbidity and mortality (1-4). Symptoms of threatened preterm delivery include uterine contractions, change of vaginal discharge, vaginal bleeding, backache, abdominal discomfort, pelvic pressure, and cramping. Diagnostic modalities for identification of threatened preterm delivery include uterine activity monitoring and performance of a digital cervical examination, which allows estimation of cervical dimensions. These methods have been shown to be limited, as minimal cervical dilatation (< 3 centimeters) and uterine activity occur normally and are not necessarily diagnostic of imminent preterm delivery (5,11,13). While several serum biochemical markers have been evaluated, none have been widely accepted for practical clinical use (6,7,20).

Fetal fibronectin (fFN), an isoform of fibronectin, is a complex adhesive glycoprotein with a molecular weight of approximately 500,000 daltons (8,9). Matsuura and co-workers have described a monoclonal antibody called FDC-6, which specifically recognizes III-CS, the region defining the junction of the maternal and fetal units within the uterus (5,10).

Fetal fibronectin can be detected in cervicovaginal secretions of women throughout pregnancy by use of a monoclonal antibody-based immunoassay. Fetal fibronectin is elevated in cervicovaginal secretions during the first 24 weeks of pregnancy but is diminished between 24 and 34 weeks in normal pregnancies. The significance of its presence in the vagina during the first 24 weeks of pregnancy is not understood. However, it may simply reflect the normal growth of the extravillous trophoblast population and the placenta. Detection of fFN in cervicovaginal secretions between 24 and 34 completed weeks gestation is reported to be associated with preterm delivery in symptomatic (5,11-15) and asymptomatic pregnant women (16-19).

PRINCIPLE OF THE TEST

The QuikCheck fFN is a solid-phase immunogold assay. Specimens obtained from the posterior fornix are placed into an extraction buffer. A test strip with immobilized mouse monoclonal anti-fetal fibronectin antibody, human fibronectin, and goat polyclonal anti-fibronectin antibody-gold conjugate is then placed in the extraction buffer. The extraction buffer migrates up the test strip by wicking action; the polyclonal antibody-gold conjugate then binds to the immobilized anti-fetal fibronectin antibody, producing a visible line. If fetal fibronectin is absent from the sample, no binding occurs to the immobilized anti-fetal fibronectin antibody. Residual unbound anti-human fibronectin polyclonal antibody-gold conjugate migrates further across the membrane and binds to immobilized plasma fibronectin, providing an assay control. A positive specimen will result in two visible lines; a negative specimen will result in one visible line.

PRECAUTIONS AND WARNINGS

1. For in vitro diagnostic use only.
2. Read the entire directional insert before performing this test and carefully follow the instructions. Modification of the assay protocol outlined in this insert may result in erroneous results.
3. Do not mix materials from different lots.
4. Do not use if applicator package integrity is compromised or if extraction buffer tube has leaked.
5. Do not use materials past their expiration dates.
6. Specimens of human origin should be considered potentially infectious. Use appropriate precautions in the collection, handling, storage, and disposal of the specimen and the used kit contents. Discard used materials in a proper biohazard container.
7. The extraction buffer contains 0.02% sodium azide, which may react with lead or copper plumbing to form potentially explosive metal azides. When disposing of this reagent, always flush the drain with large volumes of water to prevent azide build-up.
8. Handle materials with care; do not bend or compress materials.
9. The QuikCheck fFN test must be run within 15 minutes of sampling. Samples cannot be stored for later testing.
10. Care must be taken not to contaminate cervicovaginal fluid with topical agents such as lubricants, soap, disinfectants, or creams (e.g., K-Y® Jelly lubricant, Betadine® disinfectant, Monistat® cream, hexachlorophene). These substances may interfere with the specimen collection process and/or the antibody-antigen reaction of the QuikCheck fFN test.
11. The extraction buffer tube must be kept in an upright position during the assay procedure.
STORAGE AND STABILITY
All components are stable at 2° to 25°C and may be used until the expiration dates printed on the labels. Do not freeze.

REAGENTS AND MATERIALS PROVIDED
1. Sterile Applicator: One sterile polyester tipped applicator on a plastic shaft.
3. Tube with Extraction Buffer: One polypropylene tube containing 1 mL extraction buffer.

MATERIALS REQUIRED BUT NOT PROVIDED
1. Test tube rack to hold extraction buffer tube
2. Timer

SPECIMEN COLLECTION AND HANDLING
Each package contains a sterile polyester tipped applicator for specimen collection. This is the only acceptable applicator to use with this assay. Other applicator materials interfere with the assay. Cervicovaginal secretions are obtained from the posterior fornix of the vagina. The collection process is intended to be gentle. Vigorous or forceful collection, common for microbiological cultures, is not required. During a speculum examination, prior to any examination or manipulation of the cervix or the vaginal tract, lightly rotate the applicator tip across the posterior fornix of the vagina for approximately 10 seconds to absorb cervicovaginal secretions. Subsequent attempts to saturate the applicator tip may invalidate the test. Remove the applicator and immediately perform the test as directed below. Samples may not be stored for later testing.

TEST PROCEDURE
1. Before collecting the patient sample, remove the tube containing the extraction buffer from the package and carefully remove the cap.
2. Collect the patient sample as instructed above with the sterile polyester tipped applicator provided. Remove the applicator and insert the tip into the tube containing the extraction buffer and mix vigorously for 10 to 15 seconds.
3. Remove as much liquid as possible from the applicator by rolling the tip against the inside of the tube. Dispose of the applicator in a manner consistent with handling potentially biohazardous materials.
4. Remove the test strip from the foil pouch making sure to handle only the labeled portion of the test strip. Insert the lower end of the test strip (dip area indicated by the arrows) into the tube containing the extraction buffer. Do not immerse the test strip further than the dip area. Do not recap tube during test strip incubation.
5. Allow the test strip to stand in the extraction buffer for 10 minutes. Remove the test strip and read the result.
6. Dispose of the used test strip, extraction buffer tube, and extraction buffer in a manner consistent with handling potentially biohazardous materials.

INTERPRETATION OF RESULTS
The QuikCheck fFN is a qualitative test. A negative result indicating the absence of fetal fibronectin will appear as one line. A positive result indicating the presence of fetal fibronectin will appear as two lines. Lines may vary in appearance from very faint to very dark. If no lines appear or if the control line does not appear, the test must be repeated.

LIMITATIONS OF THE TEST
1. This assay can only be used for the qualitative detection of fetal fibronectin in cervicovaginal secretions.
2. Test results should always be used in conjunction with other clinical and laboratory data for patient management.
3. Specimens should be obtained prior to digital examination or manipulation of the cervix. Manipulations of the cervix may lead to false positive results.
4. Specimens should not be collected if the patient has had sexual intercourse within 24 hours to eliminate false positive results.
5. Patients with suspected or known placental abruption, placenta previa, or moderate or gross vaginal bleeding should not be tested.

EXPECTED VALUES
Among symptomatic women, elevated levels (≥ 0.050 μg/mL) (1 x 10^{-7} mmol/L) of fFN between 24 weeks, 0 days and 34 weeks, 6 days indicate increased risk of delivery in ≤ 7 or ≤ 14 days from sample collection. Among asymptomatic women, elevated levels of fFN between 22 weeks, 0 days and 30 weeks, 6 days indicate increased risk of delivery in ≤ 34 weeks, 6 days of gestation. The cutoff of 0.050 μg/mL fFN was established in a multicenter study conducted to evaluate the association between fetal fibronectin expression during pregnancy and preterm delivery (5). Calibration of QuikCheck fFN is traceable to a primary human fetal fibronectin standard that is affinity-purified using monoclonal anti-human fetal fibronectin antibody FDC-6 (8,9) and quantified spectrophotometrically.
PERFORMANCE CHARACTERISTICS

Published Clinical Studies

- Garcia, ALA, et al. Utilidad clínica de la expresión de fibronectina fetal (FNf) en secreción cervicovaginal (SCV). Ginecol Obst Mex 2002;70:379. The presence of fFN before 34 weeks of pregnancy predicts preterm delivery with a sensitivity, specificity, positive predictive value, and negative predictive value of 75%, 41%, 82%, and 95%, respectively, with a relative risk of 8.37 in a symptomatic population.


Laboratory Performance

Within-Run Precision (tests run in duplicate, repeated 6 times)

<table>
<thead>
<tr>
<th>Test</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of samples</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Test Positive/True Positive</td>
<td>12/12</td>
<td>12/12</td>
<td>12/12</td>
<td>12/12</td>
<td>12/12</td>
<td>12/12</td>
</tr>
<tr>
<td>Test Negative/True Negative</td>
<td>6/6</td>
<td>6/6</td>
<td>6/6</td>
<td>6/6</td>
<td>6/6</td>
<td>6/6</td>
</tr>
<tr>
<td>Test Positive/Borderline (50 ng/mL)</td>
<td>1/2</td>
<td>1/2</td>
<td>1/2</td>
<td>1/2</td>
<td>1/2</td>
<td>1/2</td>
</tr>
</tbody>
</table>

All 20 specimens were accurately detected with the QuikCheck fFN test.

Between-Run Precision (three test strip lots)

Tests of 12 positive samples in duplicate, 6 negative samples in duplicate and 2 borderline samples in duplicate over three lots of fFN test strips (40 tests per lot) showed 100% agreement among the lots.

Interfering Substances

Care must be taken not to contaminate the applicator or cervicovaginal secretions with lubricants, soaps, disinfectants, or creams. Lubricants or creams may physically interfere with absorption of the specimen onto the applicator. Soaps or disinfectants may interfere with the antibody-antigen reaction.

Potential interfering substances were tested at concentrations that might be reasonably found in cervicovaginal secretions. The following substances did not interfere in the assay when tested at the levels indicated.

<table>
<thead>
<tr>
<th>Substance</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampicillin</td>
<td>1.47 mg/mL</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>0.272 mg/mL</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>0.849 mg/mL</td>
</tr>
<tr>
<td>Oxytocin</td>
<td>10 IU/mL</td>
</tr>
<tr>
<td>Terbutaline</td>
<td>3.59 mg/mL</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>2.50 mg/mL</td>
</tr>
<tr>
<td>MgSO₄·7H₂O</td>
<td>1.49 mg/mL</td>
</tr>
<tr>
<td>Ritodrine</td>
<td>0.33 mg/mL</td>
</tr>
<tr>
<td>Prostaglandin F₂α</td>
<td>0.033 mg/mL</td>
</tr>
<tr>
<td>Prostaglandin E₂</td>
<td>0.033 mg/mL</td>
</tr>
<tr>
<td>Monistat® (miconazole)</td>
<td>0.5 mg/mL</td>
</tr>
<tr>
<td>Indigo Carmine</td>
<td>0.232 mg/mL</td>
</tr>
<tr>
<td>Maternal Urine 3rd Trimester</td>
<td>5% (vol)</td>
</tr>
<tr>
<td>Betadine® Gel</td>
<td>10 mg/mL</td>
</tr>
<tr>
<td>Betadine® Cleanser</td>
<td>10 mg/mL</td>
</tr>
<tr>
<td>KY® Jelly</td>
<td>62.5 mg/mL</td>
</tr>
<tr>
<td>Dermicidol® 2000</td>
<td>25.73 mg/mL</td>
</tr>
</tbody>
</table>

TROUBLESHOOTING

Q: The test line is faintly visible. Is the result positive or negative?
A: If the test line is faint but visible, the result is positive.

Q: The control line is faintly visible. Is the test valid?
A: Yes. If the control line is faint but visible, the test is valid.

Q: The test and control lines are of different intensities. Is the test valid?
A: Yes. Regardless of relative intensity, if test and control lines are visible, the test is valid.

Q: The control line is not visible. Is the test valid?
A: No. If the control line is not visible, the test is invalid. Repeat the test.

Q: The control line and/or the test line is incomplete. Is the test valid?
A: No. If the control line and/or the test line is incomplete, the test is invalid. Repeat the test.

Q: The sample was bloody. Can I use the result?
A: If the amount of vaginal bleeding is clinically judged to be minimal, the sample can be used. Patients with suspected or known placental abruption, placenta previa, or moderate or gross vaginal bleeding should not be tested. Clinical studies have demonstrated that “minimal” vaginal bleeding commonly associated with labor does not interfere with clinical interpretation of the QuikCheck fFN result. For patients with vaginal bleeding judged to be “moderate” or “gross,” the test result may be falsely positive due to the presence of small amounts of fetal fibronectin in maternal blood.
BIBLIOGRAPHY


The QuikCheck fFN test is covered by one or more U.S. patents and one or more corresponding foreign patents.

© 2004 Adeza Biomedical Corporation. All rights reserved.

KY is a registered trademark of Johnson & Johnson.

Betadine is a registered trademark of Purdue Frederick.

Monistat is a registered trademark of Ortho Pharmaceuticals.

The Adeza logo and fFN symbol are registered trademarks of Adeza Biomedical.

TECHNICAL SERVICE AND ORDERING INFORMATION
Tel: +1-408-745-0975
Fax: +1-408-745-0208
Email: customerservice@adeza.com